 2021 Third Quarter Earnings Call Summary

Centene reported strong results for the third quarter of 2021, with revenue of $32.4 billion, HBR of 88.1%, and adjusted earnings per share of $1.26. The company's performance reflects a return to normal utilization while still covering reasonable amounts of COVID costs, which seem to have peaked in August. Centene's diversified enterprise, steady performance in Medicaid and Medicare, and strong membership increase in Medicaid are all contributing to the company's growth. The company also announced several organizational changes, including the appointment of Sarah London as Vice Chairman of the Board of Directors and Brent Layton as the company's President and Chief Operating Officer.

Looking ahead to 2022, Centene plans to continue executing on its value creation plan and is monitoring several factors, including the pace of the RFP pipeline, ongoing growth in Medicare, the opportunity for improvement in marketplace license, and the COVID landscape overall. The company is committed to achieving an investment grade rating and a disciplined capital allocation framework that takes into consideration its priorities, including investing in its business, debt management, and share repurchases.

Centene also highlighted the importance of vaccine mandates in stopping the transmission of COVID and protecting those who cannot yet safely receive inoculations. The company has been a leader on this critical issue, mandating vaccinations as an additional employment benefit and supporting its members in assessing the vaccine.

Overall, Centene's third quarter results and momentum across the enterprise are strong, and the company is focused on executing across its value creation playbook.